Pharming (PHAR) Gross Profit (2020 - 2026)

Pharming (PHAR) has 7 years of Gross Profit data on file, last reported at $141.5 million in Q2 2026.

• Quarterly Gross Profit fell 8.74% year-over-year to $141.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $317.1 million (down 100.0% YoY) and the FY2025 annual result came in at $330.6 million, up 26.29% from the prior year.
• Gross Profit advanced to $141.5 million in Q2 2026, from $0.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $181300.0 billion in Q4 2024 to a low of $0.0 in Q1 2026.
• A 5-year average of $18183.4 billion and a median of $76.7 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2023 — Gross Profit surged 104509563.56% — and 2025, when it plunged 100.0%.
• Tracing PHAR's Gross Profit over 5 years: stood at $139.7 million in 2022, then surged by 104509563.56% to $146000.0 billion in 2023, then increased by 24.18% to $181300.0 billion in 2024, then sank by 100.0% to $85.4 million in 2025, then soared by 65.66% to $141.5 million in 2026.
• The last three Gross Profit figures came in at $141.5 million (Q2 2026), $0.0 (Q1 2026), and $85.4 million (Q4 2025), per Business Quant data.